BERWYN, PA - Virpax Pharmaceuticals Inc. (NASDAQ:VRPX), a company specializing in pharmaceutical preparations, announced the immediate resignation of Dr. Vanila M. Singh from its Board of Directors on Monday. The decision was made public through a filing with the U.S. Securities and Exchange Commission on Tuesday.
Dr. Singh, whose departure took effect on September 16, 2024, has not publicly disclosed the reasons for her resignation. The company has not yet announced a successor or provided details regarding the transition of her board responsibilities.
Virpax Pharmaceuticals, incorporated in Delaware and headquartered in Berwyn, Pennsylvania, operates within the pharmaceutical industry and is recognized under the trading symbol VRPX on The Nasdaq Capital Market.
The company, which is classified as an emerging growth company, is subject to the reporting requirements of the Securities Exchange Act of 1934. As such, changes in its executive team or board are significant events that require timely disclosure to investors and the public.
This development comes at a time when the pharmaceutical industry continues to face dynamic challenges and opportunities. The departure of a board member can be a notable event for a company, potentially signaling changes in governance or strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.